ACM
GILD icon

Asymmetry Capital Management’s Gilead Sciences GILD Stock Holding History

Asymmetry Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,791
Closed -$1.35M – 34
2019
Q4 		$1.35M Sell
20,791
-32,695
-61% -$2.13M 2.42% 19
2019
Q3 		$3.39M Sell
53,486
-94,795
-64% -$6.2M 7.27% 5
2019
Q2 		$10M Buy
148,281
+78,402
+112% +$5.16M 5.43% 7
2019
Q1 		$4.54M Buy
+69,879
New +$4.64M 7.59% 4
2017
Q3 		– Sell
-57,157
Closed -$4.05M – 33
2017
Q2 		$4.05M Buy
+57,157
New +$3.8M 4.8% 11

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Asymmetry Capital Management's GILD Position: Q1 2020 in Review

Asymmetry Capital Management sold out of Gilead Sciences (GILD) in Q1 2020, closing a stake of 20,791 shares — an estimated $1.35M sold.

Asymmetry Capital Management first reported a position in GILD in Q2 2017 and held it in 5 quarters. The position peaked at $10M in Q2 2019. 1,643 funds tracked by Wall St. Rank hold GILD as of Q1 2020.

  • Asymmetry Capital Management reported no remaining Gilead Sciences position as of Q1 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 20,791 Gilead Sciences shares in Q1 2020, an estimated $1.35M.
  • Asymmetry Capital Management first reported a position in Gilead Sciences in Q2 2017 and held it in 5 quarters.
  • Asymmetry Capital Management's Gilead Sciences position peaked at $10M in Q2 2019.
  • 1,643 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2020.

Based on Asymmetry Capital Management's 13F filing for Q1 2020, filed 13 May 2020.